Berberine protects against esophageal mucosal damage in reflux esophagitis by suppressing proinflammatory cytokines

Experimental and Therapeutic Medicine

Volumn 6, Issue 3, 2013, Pages 663-670

  Choo, Byung Kil ^a   Roh, Seong Soo ^b  

^a Chonbuk National University   (South Korea)

^b Daegu Haany University   (South Korea)

Author keywords

Anti inflammatory activity; Berberine; Interleukin 1; Interleukin 6; MCP 1; PAI 1; Tumor necrosis factor

Indexed keywords

BERBERINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; MALE; MUCOSA INFLAMMATION; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; REFLUX ESOPHAGITIS; STOMACH JUICE; STOMACH PH; STOMACH SECRETION; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 84880472973     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1202     Document Type: Article

References (42)

1. Mahattanadul S, Ridtitid W, Nima S, Phdoongsombut N, Ratanasuwon P and Kasiwong S: Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. J Ethnopharmacol 134: 243-250, 2011.
2. Fujiwara Y, Higuchi K, Hamaguchi M, Takashima T, Watanabe T, Tominaga K, Oshitani N, Matsumoto T and Arakawa T: Increased expression of transforming growth factor-alpha and epidermal growth factor receptors in rat chronic reflux esoph-agitis. J Gastroenterol Hepatol 19: 517-521, 2004.
3. Yoshida N: Inflammation and oxidative stress in gastroesophageal reflux disease. J Clin Biochem Nutr 40: 13-23, 2007.
4. Labenz J, Blum AL, Bayendörffer E, Meining A, Stolte M and Börsch G: Curing Helicobacter pylori infection in patients with duodenal ulcer disease may provoke reflux esophagitis. Gastroenterology 112: 1442-1447, 1997.
5. Varanasi RV, Fantry GT and Wilson KT: Decreased prevalence of Helicobacter pylori infection in gastroesophageal reflux disease. Helicobacter 3: 188-194, 1998.
6. Haruma K, Hamada H, Mihara M, Kamada T, Yoshihara M, Sumii K, Kajiyama G and Kawanishi M: Negative associated between Helicobacter pylori infection and refux esophagitis in older patients: case-control study in Japan. Helicobacter 5: 24-29, 2000.
7. Shin JM and Kim N: Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 19: 25-35, 2013.
8. Carling L, Axelsson CK, Forssell H, Stubberöd A, Kraglund K, Bonnevie O and Ekström P: Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Aliment Pharmacol Ther 12: 985-990, 1998.
9. Youssef SS, Iskandar SB, Scruggs J and Roy TM: Acute pancreatitis associated with omeprazole. Int J Clin Pharmacol Ther 43: 558-561, 2005.
10. Katz PO: Optimizing medical therapy for gastroesophageal reflux disease: state of the art. Rev Gastroenterol Disord 3: 59-69, 2003.
11. Lahiri S, Singh P, Singh S, Rasheed N, Palit G and Pant KK: Melatonin protects against experimental reflux esophagitis. J Pineal Res 46: 207-213, 2009.
12. Colin-Jones DG: Histamine-2-receptor antagonists in gastro- oesophageal refux. Gut 30: 1305-1308, 1989.
13. Doornebal J, Bijlsma R and Brouwer RM: An unknown but potentially serious side effect of proton pump inhibitors: hypo-magnesaemia. Ned Tijdschr Geneeskd 153: A711, 2009 (In Dutch).
14. Ku SK, Kim JS, Seo YB, et al: Effect of Curculigo orchioides on reflux esophagitis by suppressing proinflammatory cytokines. Am J Chin Med 40: 1241-1255, 2012.
15. Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, Romano M and Nardone G: Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 41: 380-386, 2011.
16. Allescher HD and Wagner H: STW 5/Iberogast: multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome. Wien Med Wochenschr 157: 301-307, 2007 (In German).
17. Wang XH, Jiang SM and Sun QW: Effects of berberine on human rheumatoid arthritis fibroblast-like synoviocytes. Exp Biol Med (Maywood) 236: 859-866, 2011.
18. Lou T, Zhang Z, Xi Z, Liu K, Li L, Liu B and Huang F: Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. Inflammation 34: 659-667, 2011.
19. Kuo CL, Chi CW and Liu TY: The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203: 127-137, 2004.
20. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS and Kim JB: Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 296: E955-E964, 2009.
21. Lu DY, Tang CH, Chen YH and Wei IH: Berberine suppresses neuroinflammatory responses through AMP-activated protein kinase activation in BV-2 microglia. J Cell Biochem 110: 697-705, 2010.
22. Wang Q, Zhang M, Liang B, Shirwany N, Zhu Y and Zou MH: Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS One 6: e25436, 2011.
23. Shang W, Liu J, Yu X and Zhao J: Effects of berberine on serum levels of inflammatory factors and inflammatory signaling pathway in obese mice induced by high fat diet. Zhongguo Zhong Yao Za Zhi 35: 1474-1477, 2010 (In Chinese).
24. Shen YB, Piao XS, Kim SW, Wang L and Liu P: The effects of berberine on the magnitude of the acute inflammatory response induced by Escherichia coli lipopolysaccharide in broiler chickens. Poult Sci 89: 13-19, 2010.
25. Singh P, Singh N and Palit G: Analysing the role of COX-2 in acute oesophagitis and in melatonin-exerted protection against experimental reflux oesophagitis in rats. J Pharm Pharmacol 63: 1572-1580, 2011.
26. US Environmental Protection Agency. Health Effects Test Guidelines OPPTS 870.100. Washington, US EPA, 2012.
27. McAdam E, Haboubi HN, Forrester G, Eltahir Z, Spencer-Harty S, Davies C, Griffths A P, Baxter JN and Jenkins GJ: Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are important mediators of reflux-induced cell signaling in esophageal cells. Carcinogenesis 33: 2035-2043, 2012.
28. Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC and Ho TY: Berberine suppresses inflammatory agents-induced inter-leukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol Res 56: 193-201, 2007.
29. Choi BH, Ahn IS, Kim YH, Park JW, Lee SY, Hyun CK and Do MS: Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol Med 38: 599-605, 2006.
30. Xiao HB, Sun ZL, Zhang HB and Zhang DS: Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. Pharmacol Rep 64: 889-895, 2012.
31. Jia L, Liu J, Song Z, Pan X, Chen L, Cui X and Wang M: Berberine suppresses amyloid-beta-induced inflammatory response in microglia by inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signaling pathways. J Pharm Pharmacol 64: 1510-1521, 2012.
32. Yan F, Wang L, Shi Y, et al: Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macro-phages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol 302: G504-G514, 2012.
33. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS and Kim JB: Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 296: E955-E964, 2009.
34. Yoon HD, Jeong EJ, Choi J W, Lee MS, Park MA, Yoon NY, Kim YK, Cho DM, Kim JI and Kim HR: Anti-inflammatory effects of ethanolic extracts from Codium fragile on LPS-stimulated RAW 264.7 macrophages via nuclear factor kappaB inactivation. Fish Aquat Sci 14: 267-274, 2011.
35. Rodríguez-Hernández H, Simental-Mendía L E, Rodríguez-Ramírez G and Reyes-Romero MA: Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol 2013: 678159, 2013.
36. Rieder F, Biancani P, Harnett K, Yerian L and Falk GW: Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol 298: G571-G581, 2010.
37. Gruol DL and Nelson TE: Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 15: 3307-3339, 1997.
38. Heinrich PC, Castell JV and Andus T: Interleukin-6 and acute phase response. Biochem J 265: 621-636, 1990.
39. Allan EH and Martin TJ: Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts. J Cell Physiol 165: 521-529, 1995.
40. Ortiz-Muñoz G, Martin-Ventura JL, Hernandez-Vargas P, et al: Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol 29: 525-531, 2009.
41. Wu AC, Morrison NA, Kelly WL and Forwood MR: MCP-1 expression is specifically regulated during activation of skeletal repair and remodeling. Calcif Tissue Int 92: 566-575, 2013.
42. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S and Henney AM: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268: 10739-10745, 1993.